



# Targeted Immune Pathways in Asthma – An Immunology Update

---

## CHAIR

### **Dr Li Ping Chung**

Respiratory Consultant  
Clinical Lead for Airways Disease, Fiona Stanley Hospital  
Clinical Lead for Respiratory Multidisciplinary Service,  
Silver Chain, WA  
Clinical Lead, Respiratory Health Network,  
Department of Health, WA

## SPEAKERS

### **Professor Jo Douglass**

Head, Immunology and Allergy Department, Royal Melbourne Hospital  
Clinical Professor, The University of Melbourne

### **Professor Philip Thompson**

Director of the Lung Health Clinic  
Clinical Professor at The University of WA and Curtin University,  
Head of the Molecular Genetics and Inflammation Unit,  
The Institute of Respiratory Medicine.  
Consultant Respiratory Physician, Sir Charles Gairdner Hospital

---

## DATE

Wednesday 4<sup>th</sup> September 2019

---

## TIME

6:30pm – 9:00pm

---

## VENUE

Karri Room  
Parmeila Hilton  
14 Mill St, Perth WA 6000



## CHAIR

### Dr Li Ping Chung

MBBS(Hons) FRACP, PhD

Respiratory Consultant

Clinical Lead for Airways Disease, Fiona Stanley Hospital

Clinical Lead for Respiratory Multidisciplinary Service, Silver Chain, WA

Clinical Lead, Respiratory Health Network, Department of Health, WA

## SPEAKERS

### Professor Jo Douglass

BMedSc (Hons), MBBS (Hons) Monash, MD Monash, FRACP

Head, Immunology and Allergy Department, Royal Melbourne Hospital

Clinical Professor, The University of Melbourne

### Professor Philip Thompson

MBBS, FRACP, FCCP, MRACMA, FAPSR, FTHORSOC

Director of the Lung Health Clinic

Clinical Professor at The University of WA and Curtin University

Head of the Molecular Genetics and Inflammation Unit,

The Institute of Respiratory Medicine

Consultant Respiratory Physician, Sir Charles Gairdner Hospital

## For any queries, please contact

### Naomi Burke

Novartis Respiratory Medical Science Liaison

0416171464

naomi.burke@novartis.com

TIME	ACTIVITY
6:30pm – 7:00pm	Arrival and Registration
7:00pm – 8:45pm	<b>Presentations and discussion</b>  Currently targeted immune pathways in asthma <b>Presenter:</b> <b>Professor Jo Douglass</b>  Emerging pathways of interest in asthma management <b>Presenter:</b> <b>Professor Philip Thompson</b>
8:45pm – 9:00pm	<b>Panel discussion and Q&amp;A</b>  Closing remarks and meeting close

## RSVP

Please RSVP by Tuesday 27<sup>th</sup> August 2019 via email to [alex.sharpe@novartis.com](mailto:alex.sharpe@novartis.com) with the following details:

- ① Full name
- ② Practice details
- ③ Dietary requirements (if any)

**Note:** In line with Medicines Australia Code of Conduct, hospitality, travel or other expenses of any guest, family, or traveling companion will not be paid for or subsidised by Novartis. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

Your personal information will be processed in accordance with the Novartis Privacy Policy at <https://www.novartis.com.au/privacy-policy>. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.

Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting. Novartis Pharmaceuticals Australia Pty Limited, ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113, Australia. July 2019. AU-9601. CRD3047.